Company News
- Cyclo Therapeutics Phase 3 Pivotal Program Can Begin Enrollment Per US FDA
Oct 21, 2020, 10:53 AM EDT - Cyclo Therapeutics to Present at 2020 Annual Conference for NPC Patients, Families, and Health Professionals in the United Kingdom
Sep 21, 2020, 8:00 AM EDT - Cyclo Therapeutics Inc. Announces Additional Efficacy Data from its Ongoing Phase I/II Trial using Trappsol® CycloTM Intravenously to Treat Patients with Niemann-Pick Disease Type C1 (NPC1)
Sep 8, 2020, 8:38 AM EDT - Cyclo Therapeutics Closes $2.8 Million Private Placement Led by Novit LP With $1.0 Million
Aug 27, 2020, 8:00 AM EDT - Cyclo Therapeutics Announces Presentations on Phase I and Phase I/II Trials using Trappsol® Cyclo™ Intravenously to Treat Patients with Niemann-Pick Disease Type C1 at National Niemann Pick Disease Foundation Family Support and Medical Conference
Jul 9, 2020, 11:20 AM EDT - Cyclo Therapeutics Reports on Eighteen Month Expanded Access Program in Single Alzheimer’s Patient
Jun 17, 2020, 8:00 AM EDT - Cyclo Therapeutics’ Clinical Data Webinar Recording Available on Company Website
May 26, 2020, 8:00 AM EDT - Cyclo Therapeutics Inc. Announces Positive Top Line Results from Phase I Trial and Interim Analysis of Phase I/II Trial using Trappsol® Cyclo™ Intravenously to Treat Patients with Niemann-Pick Disease Type C1 (NPC1)
May 20, 2020, 8:00 AM EDT - Cyclo Therapeutics to Hold Call for Patients and Investors Wednesday, May 20 at 4:30 pm EDT
May 19, 2020, 8:00 AM EDT - Cyclo Therapeutics Announces Positive Feedback from European Medicines Agency on its Pivotal Trial Design for Trappsol® Cyclo™ for Niemann-Pick Disease Type C1
May 18, 2020, 8:00 AM EDT
